N. Sadraei

发表

Decreased plasma DEK Oncogene Levels Correlate with p16-Negative Disease and Advanced Tumor Stage in a Case–Control Study of Patients with Head and Neck Squamous Cell Carcinoma

K. Wilson, V. Takiar, T. Wise-Draper, 2017, Translational oncology.

Phase 1 dose‐finding study of metformin in combination with concurrent cisplatin and radiotherapy in patients with locally advanced head and neck squamous cell cancer

V. Takiar, J. S. Gutkind, A. Molinolo, 2020, Cancer.

Try to Avoid Tri-Modality Treatment.

B. Huth, N. Sadraei, 2017, International journal of radiation oncology, biology, physics.

A phase I/II trial of concurrent immunotherapy with chemoradiation in locally advanced larynx cancer

V. Takiar, T. Wise-Draper, K. Redmond, 2022, Laryngoscope investigative otolaryngology.

Lymphopenia as a predictor of survival in chemoradiation-treated stage III non-small-cell lung cancer (NSCLC): a multi-center retrospective analysis

P. Fu, G. Videtic, F. Fakhrejahani, 2019, Journal of Radiation Oncology.

Phase II multi-site investigation of neoadjuvant pembrolizumab and adjuvant concurrent radiation and pembrolizumab with or without cisplatin in resected head and neck squamous cell carcinoma.

V. Takiar, A. Molinolo, N. Dunlap, 2018 .

Spatial characterization and quantification of CD40 expression across cancer types

D. Rimm, A. Psyrri, F. Ahmed, 2023, BMC Cancer.

48MO Phase I study of AMG 757, a delta-like ligand 3 (DLL3) targeting, half-life extended bispecific T-cell engager immuno-oncology therapy, in small cell lung cancer (SCLC)

R. Govindan, Melissa L. Johnson, T. Owonikoko, 2021 .

Lymphopenia as a predictor of survival in chemoradiation (CRT)-treated stage III non-small cell lung cancer (NSCLC).

G. Videtic, F. Fakhrejahani, K. Redmond, 2015 .

Updated results from a phase 1 study of AMG 757, a half-life extended bispecific T-cell engager (BiTE) immuno-oncology therapy against delta-like ligand 3 (DLL3), in small cell lung cancer (SCLC).

R. Govindan, T. Owonikoko, H. Borghaei, 2021 .

Neoadjuvant Pembrolizumab is Active in Surgically Resected Head and Neck Cancer

K. Wilson, V. Takiar, N. Dunlap, 2018 .

P2.03a-027 A Phase I Study of the Non-Receptor Tyrsine Kinase Inhibitor (NKI) Bosutinib in Combination with Pemetrexed in Patients with Advanced Solid Tumors: Topic: Clinical Trials

E. Bahassi, N. Karim, J. Morris, 2017 .

OA11.03 A Phase 1 Study of AMG 757, Half-Life Extended Bispecific T-Cell Engager (BiTE®)Immune Therapy Against DLL3, in SCLC

R. Govindan, A. Chiang, R. Salgia, 2021 .